Results 31 to 40 of about 19,887 (300)

Hepatitis C at presentation in a newly diagnosed infant with B Acute Lymphoblastic Leukemia

Pediatric Hematology Oncology Journal, 2018
We report the unique case of a nine-month old patient diagnosed with B- Cell Acute Lymphoblastic Leukemia also positive for Hepatitis C virus, genotype 3 and a high viral load.
Qurratulain Shahood Ahmed, Zehra Fadoo, Kamran Sadiq, Sadaf Altaf   +3 more
doaj   +1 more source

Broad-Spectrum Antivirals Derived from Natural Products

Viruses, 2023
Scientific advances have led to the development and production of numerous vaccines and antiviral drugs, but viruses, including re-emerging and emerging viruses, such as SARS-CoV-2, remain a major threat to human health.
Wen-Jun Tian, Xiao-Jia Wang
doaj   +1 more source

Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients

Nefrología (English Edition), 2017
Hepatitis C virus (HCV) infection is highly prevalent among patients on haemodialysis and leads to a poorer prognosis compared to patients who do not have said infection.
Soraya Abad, Almudena Vega, Diego Rincón, Eduardo Hernández, Evangelina Mérida, Nicolás Macías, Raquel Muñoz, Mónica Milla, Jose Luño, Juan Manuel López-Gómez   +9 more
doaj   +1 more source

HCV treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. [PDF]

, 2013
UNLABELLED: Substantial reductions in hepatitis C virus (HCV) prevalence among people who inject drugs (PWID) cannot be achieved by harm reduction interventions such as needle exchange and opiate substitution therapy (OST) alone. Current HCV treatment is
Dillon, John, Hellard, M, Grebely, J ; https://orcid.org/, Hellard, Margaret, Goldberg, David J., Martin, Natasha K, Goldberg, DJ, Vickerman, P, Dore, Gregory J, Goldberg, David, Hickman, M ; https://orcid.org/, Hickman, Matthew, Lima, Viviane D, Grebely, J, Hutchinson, SJ, Dillon, John F.; id_orcid, Foster, Graham R., Lima, Viviane, Hickman, M, Martin, Natasha, Hutchinson, Sharon J.; id_orcid, Lima, VD, Martin, NK, Dore, Gregory J., Foster, Graham, Lima, Viviane D., Dore, Gregory, Vickerman, Peter, Goldberg, David J, Dillon, John F, Grebely, Jason, Hutchinson, Sharon, Hutchinson, Sharon J., Foster, Graham R, Dillon, JF, Dore, GJ ; https://orcid.org/, Foster, GR, Dillon, John F., Dore, GJ, Hutchinson, Sharon J, Martin, Natasha K.   +40 more
core   +1 more source

Chronic Hepatitis C Treatment with New Antiviral Agents

Mediterranean Journal of Infection, Microbes and Antimicrobials, 2018
Recent advances in our knowledge of hepatitis C virus (HCV) molecular biology have enabled improvements in the efficacy and tolerability of HCV treatment, and in this regard many direct-acting antiviral (DAA) agents have been developed.
Özlem KANDEMİR
doaj   +1 more source

Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3. [PDF]

Turk J Gastroenterol
Background/Aims: Despite the widespread use of direct-acting antivirals (DAAs), real-world data on treatment outcomes and predictors of response in hepatitis C virus (HCV) genotypes 2 and 3 remain limited, particularly in countries with heterogeneous ...
Kaya SY, Kurtaran B, Çuvalcı NÖ, Önlen Y, Ceylan MR, Zerdali E, Sarı ND, Öncül A, Erben N, Batirel A, İnan D, Kömür S, Yıldırım FS, Yaqoobi H, Kuscu F, Guner R, Tabak F, Hep-C Türkiye Study Group.   +17 more
europepmc   +2 more sources

Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience

Annals of Hepatology, 2019
Introduction and aim: Recurrent HCV infection after liver transplant (LT) has a negative impact on graft and patient survival. The aim of this study is to describe the efficacy and safety of sofosbuvir (SOF-based) regimens in the treatment of recurrent ...
Alexandre Araujo, Vanessa Valenzuela-Granados, Antonio B. Lopes, Matheus T. Michalczuk, Augusto Mantovani, Mario R. Alvares-da-Silva   +5 more
doaj   +1 more source

Self-reported experience in patients treated with Hepatitis C direct acting antivirals [PDF]

Farmacia Hospitalaria, 2016
Background and objective: To learn about and analyze the self-reported treatment experience of HCV patients who started treatment with direct acting antivirals agents (DAA), at a real-time, proactive and integrated into the pharmaceutical care healthcare
Irene Cañamares Orbis, Javier Saez de la Fuente, Ismael Escobar Rodriguez, Concepción Esteban Alba, Ana Such Díaz, Ismael Escobar Rodríguez   +5 more
doaj   +1 more source

Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia

International Journal of Infectious Diseases, 2021
Objectives: Due to limited hepatitis C virus (HCV) sequence availability from patients in Russia, the relationship between subtypes and baseline resistance-associated substitutions (RAS) to direct antiretroviral treatment outcome is not fully understood.
Vasily Isakov, Charlotte Hedskog, Joel O. Wertheim, Reilly E. Hostager, Bandita Parhy, Adriano De Bernardi Schneider, Vithika Suri, Hongmei Mo, Natalia Geivandova, Vyacheslav Morozov, Elena Bessonova, Natalya Gankina, Konstantin Zhdanov, Dzhamal Abdurakhmanov, Evguenia Svarovskaia   +14 more
doaj   +1 more source

Update on hepatitis C: Direct-acting antivirals

World Journal of Hepatology, 2015
Hepatitis C virus (HCV) was discovered 26 years ago. For decades, interferon-based therapy has been the mainstay of treatment for HCV. Recently, several direct-acting antivirals (DAAs) have been approved for treatment of HCV-infected patients and to help combat the virus.
Leon L, Seifert, Ryan B, Perumpail, Aijaz, Ahmed   +2 more
openaire   +2 more sources